4.6 Review

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

Journal

NATURE REVIEWS CLINICAL ONCOLOGY
Volume 8, Issue 7, Pages 393-404

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2011.83

Keywords

-

Categories

Funding

  1. Scientific Research in Flanders (FWO) [G. 0532.10, G. 0651.08]
  2. Flemish Government
  3. Belgian Government, BELSPO [P60/30]
  4. Belgian Foundation
  5. Susan G. Komen Breast Cancer Foundation
  6. Leducq Network of Excellence, and Stichting Emmanuel van der Schueren (Belgium)

Ask authors/readers for more resources

All human cells, including cancer cells, need oxygen and nutrients to survive. A widely used strategy to combat cancer is therefore the starvation of tumor cells by cutting off the blood supply of tumors. Clinical experience indeed shows that tumor progression can be delayed by anti-angiogenic agents. However, emerging evidence indicates that in certain experimental conditions, hypoxia as a result of pruning of the tumor microvasculature can promote tumor invasion and metastasis, although these findings are contextual and debated. Genetic studies in mice unveiled that vascular-targeting strategies that avoid aggravation of tumor hypoxia or even promote tumor oxygenation might prevent such an invasive metastatic switch. In this article, we will discuss the emerging link between hypoxia signaling and the various steps of metastasis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available